Autor: |
Quintanilla-Sánchez, Carolina, Salcido-Montenegro, Alejandro, González-González, José Gerardo, Rodríguez-Gutiérrez, René |
Předmět: |
|
Zdroj: |
Reviews in the Neurosciences; Aug2022, Vol. 33 Issue 6, p631-639, 9p |
Abstrakt: |
The overall rate of ACVE was 7.951% ( I n i = 164/2050, 95% CI 7.602-8.299) for patients with severe COVID-19 and 2.69% ( I n i = 265/9836, 95% CI 2.136-3.251) for those with nonsevere COVID-19. Laboratory-confirmed COVID-19 From the 4769 patients with laboratory-confirmed COVID-19, 143 patients developed ACVE (2.998%, 95% CI 2.739-3.257). Keywords: COVID-19; hemorrhagic stroke; ischemic stroke; sinus venous thrombosis; stroke; transitory ischemic attack EN COVID-19 hemorrhagic stroke ischemic stroke sinus venous thrombosis stroke transitory ischemic attack 631 639 9 08/09/22 20220801 NES 220801 Introduction Since the beginning of the pandemic, patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have presented diverse neurological manifestations, being acute cerebrovascular events (ACVE) among the most important because of their related mortality and impairment of the quality of life ([4]; [15]; [17]; [18]; [23]). However, we decided to make a subanalysis of the studies that evaluated only patients with laboratory-confirmed COVID-19 and of the studies that analyzed the cohort of patients with COVID-19 and other neurological manifestations. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|